What is the ThyGeNEXT® and ThyraMIR® Panel and How Does It Help Me?
ThyGeNEXT® is a highly specific mutational panel that assesses the common oncogenic alterations across 10 genes relevant to thyroid carcinoma and 38 RNA fusion transcripts, associated with thyroid carcinoma. ThyraMIR® is the first and only microRNA gene expression classifier for thyroid nodules. When ThyGeNEXT® and ThyraMIR® are used in combination, highly predictive “rule-in” and “rule-out” malignancy risk results are obtained. ThyraMIR® can identify malignancy in nodules that are negative for ThyGeNEXT®, thereby improving overall sensitivity and ability to detect malignancy. The ThyGeNEXT® and ThyraMIR® tests provide additional risk stratifying information that impacts patient management and treatment plan.
Learn More About ThyGeNEXT® and ThyraMIR®
>>>>>>>
